- Proteins and Peptides
- Lysates and Cell Lines
Novus Biologicals and SDIX (Strategic Diagnostics Inc. d/b/a SDIX, NASDAQ: SDIX), announced today they have entered into an exclusive partnership for the creation and dissemination of premade Genomic Antibody Technology(GAT) polyclonal antibodies. Initial commercial efforts will focus on Novus dissemination of over 800 antibodies from SDIX premade collection of cancer antigen polyclonal antibodies and the creation of additional novel antibodies through the application of GAT to targets selected by Novus for inclusion in Novus catalog offering.
Genomic Antibody Technology was developed to address the growing need for high-quality reagents in the Life Science industry. GAT uses sophisticated bioinformatics and immunization strategies to produce high-value antibody reagents and biomolecules. SDIXs application of powerful proprietary algorithms enables GAT to focus antibody creation on a precise gene or protein sequence that directs the resultant antibody to specifically bind to that region of the protein in its naturally folded form. The ability of any antibody to recognize a protein naturally folded state has the potential to expand an antibody utility to high-value applications like sandwich immunoassay, ChIP, and flow cytometry.
A recognized advantage is GAT ability to produce reagents against traditionally difficult cellular targets, such as highly conserved and transmembrane proteins.
SDIX GAT technology is an exciting new addition to the Novus Biologicals product line. Through this partnership, Novus will be able to introduce high quality antibodies and biomolecules with powerful new capabilities to the worldwide research community. The creation of this relationship with SDIX will continue to strengthen Novus image as a leader in the research products marketplace. It is pleasure to be working with a company who shares our passion for quality and scientific advancementâ€ said Ms. Karen Padgett, Novus President and CEO.
Also commenting on the announcement, Mr. Fran DiNuzzo, President and CEO of SDIX said, We are extremely pleased to be partnering with such a premier company who is focused on developing unique products at the forefront of science. We believe that Novus brand and core capabilities, in combination with SDIX competencies to create novel biomolecules will enable the rapid expansion of high quality biological materials for the research community. This partnership is another step in demonstrating SDIX commitment to creating advantage for customers by providing quality, innovative, and effective immuno-solutions to the Life Science market.
Financial terms of the partnership were not disclosed.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals, LLC is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals was organized to provide the biological research community with a mechanism for commercializing unique biological materials. The company focuses on continually monitoring scientific trends and supply materials to serve these trends. By making these products widely available to institutional and commercial researchers, Novus Biologicals plays an important role in furthering biological research. By serving niche and emerging markets, Novus Biologicals has become specialists in markets and has formed and will continue to form ongoing partnerships with our customers.
About SDIX (www.sdix.com)
SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the Pharmaceutical, Biotechnology, Diagnostics, and Food Safety markets. For nearly 20 years, SDIX has developed antibodies which advance its customersâ€™ immuno-based work â€“ reducing time, labor, and costs while increasing accuracy and reliability of results.
SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide mechanisms for rapid diagnosis.
This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like anticipate,could, enable, estimate, intend, expect, believe, potential, will, should, project, plan and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.
|NOVUS Contact:||SDIX Contact:|
|Karen Padgett||Deborah Day Barbara|
|President and CEO||Vice President, Business Development|